De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy:Network-analysis and systematic review  

作　　者：Hanxu Guo Chengqi Jin Li Ding Jun Xie Jing Xu Ruiliang Wang Hong Wang Changcheng Guo Jiansheng Zhang Bo Peng Xudong Yao Jing Yuan Bin Yang 

机构地区：[1]Department of Urology,Shanghai Tenth People’s Hospital,Tongji University School of Medicine,Shanghai 200072,China [2]Department of Urology,Urologic Cancer Institute,Tongji University School of Medicine,Shanghai 200072,China [3]Department of Urology,School of Medicine,Anhui University of Science and Technology,Huainan,Anhui 232001,China [4]Department of Urology,Shanghai Clinical College,Anhui Medical University,Shanghai 200072,China [5]Department of Urology,Shanghai Tenth People’s Hospital,Nanjing Medical University,Nanjing,Jiangsu 210029,China

出　　处：《Chinese Medical Journal》2025年第2期231-233,共3页中华医学杂志(英文版)

基　　金：funded by grants from the Shanghai Science Committee Foundation(No.19411967700);the National Natural Science Foundation of China(No.31570993);the Wu Jieping Medical Foundation(No.320.6750.2020-14-7).

摘　　要：To the Editor:In recent years,the treatment for metastatic hormone-sensitive prostate cancer(mHSPC)has undergone rapid developments.Docetaxel(DOC)or androgen receptor-targeted agent(ARTA)and androgen deprivation therapy(ADT)are the most commonly used systemic therapies.Multiple meta-analyses or network meta-analyses(NMAs)have been undertaken to evaluate and contrast the various treatment options available for mHSPC.However,the clinical efficacy of DOC in triplet therapy for mHSPC is yet to be confirmed,especially in categorizing the patients based on both volume of disease and timing of metastases.Bringing these controversies to light may have a timely and important impact on further clinical trials.Moreover,based on these trials and our NMA study,triplet therapy has evident benefits on overall survival(OS)and progression-free survival(PFS)in patients with mHSPC.The NMA study presented in this thesis is one of the first studies that assessed the efficacy of DOC and selected patients who will benefit from triplet therapy.

关 键 词：triplet therapy network meta analysis DOCETAXEL androgen deprivation therapy adt systemic therapiesmultiple overall survival progression free survival 

分 类 号：R737.25[医药卫生—肿瘤]